Haemonetics reports Q3 adjusted EPS $1.04, consensus 94c

Reports Q3 revenue $336.25M, consensus $320.29M. Chris Simon, Haemonetics’ CEO, stated: “We continue to deliver increased revenue and margins, strengthen market leadership and increase impact through portfolio evolution, operational excellence and resource allocation. Outperformance is funding additional opportunities for accelerated growth and diversification like the OpSens acquisition. We are well-positioned and gaining momentum to achieve long-term transformational growth.”